Cytosorbents (CTSO) Projected to Post Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Cytosorbents to announce earnings of ($0.05) per share and revenue of $9.3850 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The company had revenue of $8.86 million for the quarter, compared to the consensus estimate of $9.40 million. Cytosorbents had a negative net margin of 31.85% and a negative return on equity of 235.57%. On average, analysts expect Cytosorbents to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Down 4.3%

Shares of NASDAQ:CTSO opened at $0.35 on Thursday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 4.70. The stock has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.57. Cytosorbents has a 12-month low of $0.35 and a 12-month high of $1.22. The stock has a market capitalization of $22.25 million, a price-to-earnings ratio of -1.86 and a beta of 1.39.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Cytosorbents currently has an average rating of “Hold” and an average target price of $5.38.

Insider Buying and Selling at Cytosorbents

In other news, CEO Phillip P. Chan acquired 251,136 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average cost of $0.40 per share, for a total transaction of $100,454.40. Following the acquisition, the chief executive officer directly owned 1,734,099 shares in the company, valued at approximately $693,639.60. The trade was a 16.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 7.80% of the stock is owned by company insiders.

Institutional Trading of Cytosorbents

A number of institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC lifted its holdings in shares of Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in Cytosorbents in the 3rd quarter worth about $161,000. Vanguard Group Inc. raised its position in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after buying an additional 79,535 shares during the last quarter. Finally, Avenir Corp lifted its stake in Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after acquiring an additional 147,261 shares during the period. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.